FindTrial
Sign In

Interferon-alpha-2b

DRUG3 trials

Sponsors

University of Arkansas, Dermatologic Cooperative Oncology Group, BriaCell Therapeutics Corporation

Conditions

AdjuvantBreast NeoplasmBreastcancerInterferon AlphaMultiple MyelomaStage III Malignant MelanomaTherapy

Phase 1

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
CompletedNCT03066947
BriaCell Therapeutics CorporationBreastcancer, Breast Neoplasm
Start: 2017-05-05End: 2018-11-22Updated: 2021-01-29

Phase 3

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
CompletedNCT00083551
University of ArkansasMultiple Myeloma
Start: 1998-08-31End: 2014-08-31Updated: 2015-11-23
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
NCT00226408
Dermatologic Cooperative Oncology GroupAdjuvant, Interferon Alpha, Stage III Malignant Melanoma +1
Start: 2003-11-30End: 2005-09-30Target: 600Updated: 2006-06-21

Related Papers

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.
2025-06-12
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
JAMA Oncology2025-06-051 citations
Abstract PO2-13-06: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response
Cancer Research2024-05-021 citations
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.
Journal of Clinical Oncology2023-06-011 citations
Abstract CT143: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer
Cancer Research2023-04-14
Abstract P3-07-12: Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell Therapeutic Vaccine in Advanced Metastatic Breast Cancer
Cancer Research2023-03-01
Abstract P1-05-28: Decreases in Circulating Tumor Associated Cells Predicts PFS and OS In A Pooled Analysis Of Phase I Clinical Trials Using SV-BR-1-GM Therapy With Or Without Immune Check-Point Inhibitors In Metastatic Breast Cancer Patients
Cancer Research2023-03-01
Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
Blood2022-11-151 citations
Abstract P2-14-02: Overall survival following treatment with a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
Cancer Research2022-02-15
Abstract CT102: Predictors of response to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I/IIa trials
Cancer Research2021-07-01
Abstract PS17-20: Response to a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer correlates with tumor grade
Cancer Research2021-02-15
Abstract 5588: Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials
Cancer Research2020-08-15
Abstract P3-09-08: Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors
Cancer Research2020-02-151 citations
Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer.
Journal of Clinical Oncology2019-05-201 citations
Targeted tumor-derived cellular immunotherapy in advanced breast cancer patients induces initial immune responses and tumor regression.
Journal of Clinical Oncology2019-03-10
Abstract P2-09-09: Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
Cancer Research2019-02-15
Abstract A012: SV-BR-1-GM, a whole-cell targeted immunotherapy for advanced breast cancer: Pharmacodynamic markers of response
Cancer Immunology Research2019-02-01
Abstract CT171: Safety and efficacy of a whole-cell targeted immunotherapy for breast cancer: Preliminary findings
Cancer Research2018-07-01
Abstract 5632: Targeted immunotherapy with SV-BR-1-GM: Mechanism of action and companion diagnostic development
Cancer Research2018-07-01
SV-BR-1-GM a whole-cell targeted immunotherapy for breast cancer: Preliminary clinical data.
Journal of Clinical Oncology2018-05-20

4 more papers not shown